The current understanding on the impact of KRAS on colorectal cancer

被引：104

作者：

Meng, Mingjing ^{[1
]}

Zhong, Keying ^{[1
]}

Jiang, Ting ^{[1
]}

Liu, Zhongqiu ^{[1
,2
]}

Kwan, Hiu Yee ^{[3
]}

Su, Tao ^{[1
,2
]}

机构：

[1] Guangzhou Univ Chinese Med, Sch Pharmaceut Sci, Int Inst Translat Chinese Med,Minist Educ Peoples, Guangdong Key Lab Translat Canc Res Chinese Med,J, Guangzhou, Guangdong, Peoples R China

[2] Guangzhou Univ Chinese Med, Guangdong Hong Kong Macau Joint Lab Chinese Med &, Guangzhou, Guangdong, Peoples R China

[3] Hong Kong Baptist Univ, Ctr Canc & Inflammat Res, Sch Chinese Med, Hong Kong, Peoples R China

来源：

BIOMEDICINE & PHARMACOTHERAPY | 2021年 / 140卷

基金：

中国国家自然科学基金;

关键词：

Colorectal cancer; KRAS; Mutation; Therapy; CONSENSUS MOLECULAR SUBTYPES; ANTI-EGFR THERAPY; MUTANT KRAS; K-RAS; ONCOGENIC KRAS; MICROSATELLITE INSTABILITY; 1ST-LINE TREATMENT; MUTATION ANALYSIS; LIVER METASTASES; POOR-PROGNOSIS;

D O I：

10.1016/j.biopha.2021.111717

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

KRAS (kirsten rat sarcoma viral oncogene) is a member of the RAS family. KRAS mutations are one of most dominant mutations in colorectal cancer (CRC). The impact of KRAS mutations on the prognosis and survival of CRC patients drives many research studies to explore potential therapeutics or target therapy for the KRAS mutant CRC. This review summarizes the current understanding of the pathological consequences of the KRAS mutations in the development of CRC; and the impact of the mutations on the response and the sensitivity to the current front-line chemotherapy. The current therapeutic strategies for treating KRAS mutant CRC, the difficulties and challenges will also be discussed.

引用

页数：13

共 164 条

[71] Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing [J].

Kothari, Nishi ;

Schell, Michael J. ;

Teer, Jamie K. ;

Yeatman, Timothy ;

Shibata, David ;

Kim, Richard .

JOURNAL OF CLINICAL PATHOLOGY, 2014, 67 (09) :764-767

[72] KRAS Mutation and Consensus Molecular Subtypes 2 and 3 Are Independently Associated withReducedImmuneInfiltrationandReactivity in Colorectal Cancer [J].

Lal, Neeraj ;

White, Brian S. ;

Goussous, Ghaleb ;

Pickles, Oliver ;

Mason, Mike J. ;

Beggs, Andrew D. ;

Taniere, Philippe ;

Willcox, Benjamin E. ;

Guinney, Justin ;

Middleton, Gary W. .

CLINICAL CANCER RESEARCH, 2018, 24 (01) :224-233

[73] Optimized Allele-Specific Real-Time PCR Assays for the Detection of Common Mutations in KRAS and BRAF [J].

Lang, Alois H. ;

Drexel, Heinz ;

Geller-Rhomberg, Simone ;

Stark, Nicole ;

Winder, Thomas ;

Geiger, Kathrin ;

Muendlein, Axel .

JOURNAL OF MOLECULAR DIAGNOSTICS, 2011, 13 (01) :23-28

[74] Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer [J].

Laurent-Puig, Pierre ;

Cayre, Anne ;

Manceau, Gilles ;

Buc, Emmanuel ;

Bachet, Jean-Baptiste ;

Lecomte, Thierry ;

Rougier, Philippe ;

Lievre, Astrid ;

Landi, Bruno ;

Boige, Valerie ;

Ducreux, Michel ;

Ychou, Marc ;

Bibeau, Frederic ;

Bouche, Olivier ;

Reid, Julia ;

Stone, Steven ;

Penault-Llorca, Frederique .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) :5924-5930

[75] KRAS Mutation is Associated with Worse Prognosis in Stage III or High-risk Stage II Colon Cancer Patients Treated with Adjuvant FOLFOX [J].

Lee, Dae-Won ;

Kim, Kyung Ju ;

Han, Sae-Won ;

Lee, Hyun Jung ;

Rhee, Ye Young ;

Bae, Jeong Mo ;

Cho, Nam-Yun ;

Lee, Kyung-Hun ;

Kim, Tae-Yong ;

Oh, Do-Youn ;

Im, Seock-Ah ;

Bang, Yung-Jue ;

Jeong, Seung-Yong ;

Park, Kyu Joo ;

Park, Jae-Gahb ;

Kang, Gyeong Hoon ;

Kim, Tae-You .

ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (01) :187-194

[76]

Lee SH, 2017, J PATHOL TRANSL MED, V51, P24, DOI 10.4132/jptm.2016.10.03

[77] Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors [J].

Li, Hui ;

Zhang, Jinglin ;

Tong, Joanna Hung Man ;

Chan, Anthony Wing Hung ;

Yu, Jun ;

Kang, Wei ;

To, Ka Fai .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (23)

[78] A Highly Verified Assay for KRAS Mutation Detection in Tissue and Plasma of Lung, Colorectal, and Pancreatic Cancer [J].

Li, Jing ;

Gan, Stephanie ;

Blair, Alan ;

Min, Kyungji ;

Rehage, Taraneh ;

Hoeppner, Corey ;

Halait, Harkanwal ;

Brophy, Victoria H. .

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2019, 143 (02) :183-189

[79] Development of synthetic lethality in cancer: molecular and cellular classification [J].

Li, Shijie ;

Topatana, Win ;

Juengpanich, Sarun ;

Cao, Jiasheng ;

Hu, Jiahao ;

Zhang, Bin ;

Ma, Diana ;

Cai, Xiujun ;

Chen, Mingyu .

SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2020, 5 (01)

[80]

Li WH, 2019, INT J CLIN EXP PATHO, V12, P957

← 3 4 5 6 7 8 9 10 11 12 →